Pacira BioSciences, Inc.
PCRX
$23.00
-$0.18-0.78%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.71% | 4.57% | 3.63% | 3.14% | 2.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.71% | 4.57% | 3.63% | 3.14% | 2.25% |
| Cost of Revenue | 4.37% | 0.02% | -8.91% | -16.21% | -14.07% |
| Gross Profit | 6.08% | 5.88% | 7.66% | 9.82% | 7.97% |
| SG&A Expenses | 15.14% | 21.72% | 25.39% | 23.72% | 20.23% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.78% | 15.96% | 15.78% | 10.83% | 8.19% |
| Operating Income | -60.07% | -72.75% | -71.51% | -41.53% | -32.32% |
| Income Before Tax | 116.56% | 119.35% | 126.74% | 176.17% | -205.97% |
| Income Tax Expenses | -85.60% | -77.50% | -73.01% | -43.07% | -43.42% |
| Earnings from Continuing Operations | 111.48% | 104.95% | 107.07% | 123.63% | -300.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 111.48% | 104.95% | 107.07% | 123.63% | -300.43% |
| EBIT | -60.07% | -72.75% | -71.51% | -41.53% | -32.32% |
| EBITDA | -28.66% | -32.50% | -32.52% | -18.41% | -9.54% |
| EPS Basic | 112.72% | 105.66% | 107.37% | 123.74% | -301.59% |
| Normalized Basic EPS | -53.68% | -83.67% | -77.30% | -44.82% | -38.86% |
| EPS Diluted | 112.42% | 105.17% | 106.76% | 122.13% | -307.43% |
| Normalized Diluted EPS | -52.92% | -83.00% | -75.99% | -42.23% | -33.96% |
| Average Basic Shares Outstanding | -9.56% | -6.66% | -3.63% | -1.78% | -0.80% |
| Average Diluted Shares Outstanding | -9.89% | -9.59% | -9.34% | -7.69% | -9.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |